SAN DIEGO, Nov. 11, 2011 /PRNewswire/ -- Gen-Probe
Incorporated (NASDAQ: GPRO) announced today that the Company will
present at three upcoming investor conferences:
- The Lazard Capital Markets 8th Annual Healthcare Conference in
New York at 1:30 pm Eastern Time (ET) on November 15.
- The Stephens Fall Investment Conference in New York at 11 am
ET on November 16.
- The 23rd Annual Piper Jaffray Healthcare Conference in
New York at 8 am ET on November
29.
Each presentation will be webcast live and may be accessed
through a link on the investors section of Gen-Probe's website at
www.gen-probe.com. The webcasts will be available for 30 days
following the events.
About Gen-Probe
Gen-Probe is a global leader in the development, manufacture and
marketing of rapid, accurate and cost-effective molecular
diagnostic products and services that are used primarily to
diagnose human diseases, screen donated human blood, and ensure
transplant compatibility. Gen-Probe is headquartered in
San Diego and employs
approximately 1,400 people. For more information, go to
http://www.gen-probe.com.
Caution Regarding Forward-Looking Statements
Any statements in this press release about our expectations,
beliefs, plans, objectives, assumptions, or future events or
performance are not historical facts and are forward-looking
statements. Forward-looking statements are not guarantees of
performance. They involve known and unknown risks,
uncertainties and assumptions that may cause actual results to
differ materially from those expressed or implied. For
information about risks and uncertainties we face and a discussion
of our financial statements and footnotes, see documents we have
filed with the SEC, including our most recent Form 10-K, and all
subsequent periodic filings. We assume no obligation and
expressly disclaim any duty to update any forward-looking statement
to reflect events or circumstances after the date of this press
release or to reflect the occurrence of unanticipated events.
Contact:
Paula Izidoro
Investor Relations
858-410-8904
SOURCE Gen-Probe Incorporated